Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT07083492
Recruiting Observational

Non-invasive Detection of Iron Deficiency in Obstetrics

NCT07083492 · tracked via the Priya Life Science Germany tracker
Sponsor
Wuerzburg University Hospital
Phase
Observational
Started
2022-11-15
Last updated
2025-07-24

Condition(s) studied

Iron Deficiency Anemia of PregnancyIron-deficiencyRestless Leg Syndrome in PregnancyRestless Leg Syndrome Due to Iron Deficiency AnaemiaPostpartum HemorrhagePostpartum DepressionPregnancy AnemiaIron Deficiency (Without Anemia)

Investigational drug(s) / intervention(s)

non-invasive measurement of zink protoporphyrin

non-invasive measurement of zink protoporphyrin: validation of non-invasive measurement of zink protoporphyrin

Study summary

Validation of non-invasive measurement of zinc protoporphyrin for detection of iron deficiency in pregnancy.

In addition, the impact of iron deficiency on the incidence of postpartum depression, restless legs syndrome, obstetric complications and quality of life will be examined.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * any timepoint during or up to 3 months after pregnancy * age ≥ 18 years * written informed consent Exclusion Criteria: * previous participation in this study * refusal of blood sampling * incapacity to give informed consent

Primary outcome measure(s)

  • Accuracy of non-invasive zinc protoporphyrin for the detection of iron deficiency in pregnancy — through study completion, up to 3 months postpartum
    To validate accuracy of non-invasively measured ZnPP for detection of iron deficiency in pregnancy at prespecified timepoints

Trial sites (1)

FacilityCityRegionStatus
University Hospital Würzburg Würzburg Bavaria Recruiting

More Wuerzburg University Hospital trials in Germany

Decrease Caregiving Fatigue in Group Leaders of a Support Group for Women After Cancer Enrolling by invitation
Giant Cell Arteritis - Ways to Precision Medicine Recruiting
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas Active, not recruiting
ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos Recruiting
Liquid Biopsy Under PSMA Radioligand Therapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07083492 on ClinicalTrials.gov ↗ ← All trials in Germany